Catch a Falling Star

Serono's €104.7 cash offer for France's Genset came just in time for the cash-strapped genomics play, once the star of French biotech. Critics claim Serono's 195% premium for an almost-bankrupt company is nothing short of crazy, but Serono reckons it's spotted an unexploited asset.

More from Business Strategy

More from In Vivo